Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GLS | O94925 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344916 | 1.00 | NR1H2 (0.59) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1785894 | 1.00 | NR1H2 (0.59) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31421369 | 0.95 | NR1H2 (0.57) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31421589 | 0.95 | NR1H2 (0.57) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2071987 | 0.95 | NR1H2 (0.57) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL7448268 | 0.93 | NR1H2 (0.52) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL514696 | 0.90 | NR1H2 (0.62) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL515486 | 0.90 | NR1H2 (0.62) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL621267 | 0.90 | NR1H2 (0.62) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL16863978 | 0.90 | NR1H2 (0.58) | NR1H2MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 898 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109988098-A | The synthetic method of one kind (R)-N- tertbutyloxycarbonyl -3- hydroxymethyl piperidine | 常州工程职业技术学院 | 2019-07-09 | — | — | CN | claimed |
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | claimed |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-12630551-B2 | Endocyclic pyrimidinone compounds, and preparation methods, compositions and use thereof | NEUSCO BIOTECH LIMITED (CN) | 2026-05-19 | — | — | US | disclosed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4695259-A1 | TRICYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| WO-1994013291-A1 | USE OF ARYLOXYALKYL SUBSTITUTED CYCLIC AMINES AS CALCIUM CHANNEL ANTAGONISTS AND NEW PHENYLOXYALKYL PIPERIDIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1994-06-23 | — | — | WO | disclosed |
| EP-0601459-A2 | Sulfonamido heterocyclic thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-06-15 | — | — | EP | disclosed |
| WO-1994011382-A1 | ANTINEOPLASTIC HETERONAPHTHOQUINONES | BIOCHEM PHARMA INC. (CA) | 1994-05-26 | — | — | WO | disclosed |
| US-5260307-A | Inhibit thrombin-induced platlet aggregation and clotting of fibrogen in plasma | HOFMANN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0559046-A1 | N-amidinopiperidinyl(3/4)- or N-amidino-1,4-Oxazinyl(2)-substituted sulfonamides, process for their preparation and use as thrombin inhibitors | F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) | 1993-09-08 | — | — | EP | disclosed |
| EP-0495750-A2 | Heterocyclic hydroxylamine | CIBA-GEIGY AG (CH) | 1992-07-22 | — | — | EP | disclosed |
| EP-0468231-A2 | Guanidins | F. HOFFMANN-LA ROCHE AG (CH) | 1992-01-29 | — | — | EP | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | KIF2C, KIF5B, KIF5C | NR1H2 745/4885MEN1 4063/4885ALDH1A1 2556/4885 |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | NR1H2 2747/4885MEN1 3020/4885ALDH1A1 999/4885 |
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | BRAF, RAF1, NRAS | NR1H2 4110/4885MEN1 568/4885ALDH1A1 1302/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | NR1H2 2728/4885MEN1 34/4885ALDH1A1 3351/4885 |
| US-12630551-B2 | Endocyclic pyrimidinone compounds, and preparation methods, compositions and use thereof | LPAR1, PLA2R1, LPAR2 | NR1H2 57/4885MEN1 4367/4885ALDH1A1 1113/4885 |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | NR1H2 908/4885MEN1 3585/4885ALDH1A1 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.